Clinical Trials · NCT05147896
Semaglutide Anti-Atherosclerotic Mechanisms of Action Study in Type 2 Diabetes Patients
- Phase
- N/A
- Recruitment status
- Unknown
- Sponsor
- University Medical Centre Ljubljana
- Enrollment
- 100
- Start date
- May 2022
- Locations
- 1 site, Slovenia
- Primary endpoint
- Change in morphological arterial wall characteristics